Eric Fung of Ciphergen Biosystems has been promoted to vice president for clinical and medical affairs in the company’s diagnostics division. He joined Ciphergen in 2000 as a lead scientist in its biomarker discovery center laboratories. Fung holds an MD and a PhD in molecular neuroscience from Johns Hopkins University School of Medicine, and a BS in biology from Caltech.
Ken Welsh has been appointed to the scientific advisory board of Health Discovery Corporation, a biotechnology company focused on biomarker and pathway discovery for diagnostic markers and drug targets. Welsh is a professor of clinical genomics at Royal Brompton Hospital and Imperial College in London. He received Bsc, PhD, and DSc degrees from Newcastle University.
CeMines has appointed Wenpei Su as the company’s first director of genomics applications. Su joins CeMines from the Dow Chemical Company, where he led an effort to produce therapeutic proteins. Prior to this, he was employed by Torrey Mesa Research Institute, where as a project leader he applied proteomic and gene-profiling technology to isolate genes involved in complex biological traits. Su holds a PhD in molecular biology and biochemistry from Cornell University.
Syrrx has promoted Jeffrey Stafford to vice president of chemistry. Stafford joined the company in 2002 as senior director of chemistry following an 11-year tenure at GlaxoSmithKline, where he held the position of director of chemistry in oncology.
Iain Mattaj will become director-general of the European Molecular Biology Laboratory, based in Heidelberg, following the departure of Fotis Kafatos, whose term ends next May. Mattaj joined EMBL in 1985, and was appointed scientific director for the organization in 1999. Mattaj will be EMBL’s fourth director-general since the laboratory was founded in 1974.